Skip to content
HowShorted

Relay Therapeutics, Inc. short interest in 2021

In 2021, Relay Therapeutics, Inc.'s disclosed short interest ran from 7.47% of shares outstanding on 15 Jan 2021 to 12.67% on 31 Dec 2021, a change of +5.20 percentage points. The year's high was 13.78% on 15 Oct 2021 and its low 5.90% on 12 Feb 2021, averaging 10.11% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 30.84 days on 30 Jul 2021. Full history: Relay Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Relay Therapeutics, Inc. in 2021

2021 in figures

Start of year
7.47% (15 Jan 2021)
End of year
12.67% (31 Dec 2021)
Change
+5.20 pp
High
13.78% (15 Oct 2021)
Low
5.90% (12 Feb 2021)
Average
10.11%
Highest days to cover
30.84 (30 Jul 2021)
SEC filings marked
10

Every report in 2021

Relay Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20217.47%6.30
29 Jan 20216.08%9.86
12 Feb 20215.90%11.01
26 Feb 20217.09%11.13
15 Mar 20217.37%10.13
31 Mar 20219.05%8.2110-K filed, results (8-K)
15 Apr 20218.37%12.14
30 Apr 20219.21%22.70results (8-K)
14 May 20219.23%12.7510-Q filed, results (8-K)
28 May 20219.61%22.91
15 Jun 20219.27%16.58
30 Jun 20219.92%12.42
15 Jul 202110.14%23.56
30 Jul 202110.89%30.84
13 Aug 202111.26%18.7710-Q filed, results (8-K)
31 Aug 202111.16%19.52
15 Sep 202110.79%13.82
30 Sep 202111.38%14.92
15 Oct 202113.78%6.26results (8-K)
29 Oct 202113.61%24.99
15 Nov 202112.44%24.5510-Q filed, results (8-K)
30 Nov 202112.77%25.49
15 Dec 202113.19%28.75
31 Dec 202112.67%24.55

See also: Relay Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.